Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jan 2021

Hestetun Kjersti Elvestad, Aasebø Kristine, Rosenlund Nina Benedikte, Müller Yvonne, Dahl Olav, Myklebust Mette Pernille

Abstract excerpt

Mismatch repair (MMR) deficiency is an indicator of good prognosis in localized colon cancer but also associated with lack of expression of caudal-type homeobox transcription factor 2 (CDX2) and high tumor grade; markers that in isolation indicate a poor prognosis. Our study aims to identify clinically relevant prognostic subgroups by combining information about tumor grade, MMR phenotype, and CDX2 expression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CDX2 Transcription Factor
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colectomy

Share to Colonic Neoplasms

Share to DNA Mismatch Repair

Share to DNA Repair Enzymes

Share to Neoplasm Grading

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 32737450
DOI: 10.1038/s41379-020-0634-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.PMID 32737450Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerSemantic proximity Read ↗

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.Semantic proximity Read ↗

The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.Semantic proximity Read ↗

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.Semantic proximity Read ↗

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.Semantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.Semantic proximity Read ↗

Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair DeficiencySemantic proximity Read ↗

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.